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Abstract: Nanotechnology remains the field to explore in the quest to enhance therapeutic 
efficacies of existing drugs. Fabrication of a methacrylate copolymer-lipid nanoparticulate 
(MCN) system was explored in this study for oral drug delivery of levodopa. The 
nanoparticles were fabricated employing multicrosslinking technology and characterized 
for particle size, zeta potential, morphology, structural modification, drug entrapment 
efficiency and in vitro drug release. Chemometric Computational (CC) modeling was 
conducted to deduce the mechanism of nanoparticle synthesis as well as to corroborate the 
experimental findings.  The CC modeling deduced that the nanoparticles synthesis may 
have followed the mixed triangular formations or the mixed patterns. They were found to 
be hollow nanocapsules with a size ranging from 152 nm (methacrylate copolymer) to  
321 nm (methacrylate copolymer blend) and a zeta potential range of 15.8–43.3 mV. The 
nanoparticles were directly compressible and it was found that the desired rate of drug 
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release could be achieved by formulating the nanoparticles as a nanosuspension, and then 
directly compressing them into tablet matrices or incorporating the nanoparticles directly 
into polymer tablet matrices. However, sustained release of MCNs  was achieved only 
when it was incorporated into a polymer matrix. The experimental results were well 
corroborated by the CC modeling. The developed technology may be potentially useful for 
the fabrication of multi-crosslinked polymer blend nanoparticles for oral drug delivery. 
Keywords:  nanotechnology;  nanoparticles;  nanocapsules;  methacrylate copolymer; 
chitosan; oral drug delivery; bioavailability; crosslinking; molecular mechanics simulations 
 
1. Introduction 
Despite the challenges posed by the oral route on certain drugs such as Narrow Absorption Window 
drugs and alternative routes being employed, the convenience of the oral route impels the quest to 
enhance peroral delivery of drugs. Poor or suboptimal therapeutic efficacy is usually obtained from 
drugs due to poor oral  bioavailability which could be caused by biopharmaceutical, physiological  
or drug inherent factors. The two major factors affecting bioavailability are absorption and   
metabolism [1], while other sub-factors relating to these two major factors are the physicochemical, 
biopharmaceutical and physiological factors such as solubility, permeability, particle size, chemical 
nature of the drug, enzymes, membrane transporters, effects of foods, gastrointestinal transit time, pH 
as well as the type and process of the formulation [2–4]. Technologies that have been employed to 
improve oral bioavailability include micronization [5,6], prodrugs [7–9], salt formation [10], 
absorption enhancement [11], wetting (with a  wetting agent) and spray drying [12], solid   
dispersions [13,14], micellation [15], emulsification [16,17], micro- and nano-emulsification [18–21], 
self-emulsification [22,23], utilization of cyclodextrins [24,25], chemical modification [26,27], 
sustained drug delivery, gastroretention and more recently, nanotechnology [28,29]. 
Nanotechnology is the study, fabrication, characterization and application of structures and 
materials at the nanometer scale. Pharmaceutical Nanotechnology employs mainly polymers to design, 
fabricate, characterize and apply nano-carriers for therapeutic purposes. While the field of engineering 
may describe nanoparticles as particles within 0.1–100 nm, nano-drug carriers are less than 1 μ [30,31], 
which is mainly due to the fact that they are fabricated with macromolecules, natural and synthetic 
polymers, lipids and proteins. Nanostructures that have been employed for drug delivery include 
polymeric nanoparticles, liposomes, dendrimers, nanoemulsion, solid lipid nanoparticles, nanocapsules 
and polymeric nanomicelles [32–39]. 
Nanotechnology has been employed to improve bioavailability of certain drugs where the difference 
when compared to the conventional system has been found to be significant. An in vivo study of 
curcumin-loaded nanoparticles was found to have increased in bioavailability by at least nine-fold 
compared to curcumin administered with piperine as an absorption enhancer [40]. Other drugs with 
oral bioavailability enhanced by nanotechnology include cyclosporin-A [41], amphotericin B [42], 
insulin [43,44], HIV-1 protease inhibitors [45], elcatonin [46], paclitaxel [47], estradiol [48], salmon 
calcitonin [49], camptothecin [50] and mifepristone [51]. Int. J. Mol. Sci. 2011, 12                       
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Nanostructures are fabricated utilizing a combination of technologies which include   
polymerization [52,53], emulsion solvent evaporation [54], salting out, emulsification-diffusion and 
nanoprecipitation [55–57]; supercritical fluid technology [58,59], coacervation and ionic 
gelation/crosslinking [60–62]. Crosslinking is a process of introducing bonds which may be chemical 
(covalent bonds) or physical (ionic bonds) between chains of the same material or different materials. 
It is basically an interaction that joins two molecular units thereby altering the material for 
characterization and improved functional properties.  
The aim of this study therefore, was to explore the feasibility of preparing levodopa-loaded 
nanoparticles from a  methacrylate copolymer/methacrylate copolymer blend  and  explore  various 
approaches of achieving sustained drug release from the nanoparticles. The method employed involved 
the application of miscible polymers in interaction with a phospholipid as the lipid component and a 
crosslinking agent with subsequent addition of a sequestrator as another crosslinking agent in a multi-
crosslinking technology to fabricate polymer-lipid (poly-lipo) nanoparticles. The nanoparticles were 
characterized by employing techniques such as: (i) size and surface analysis; (ii) morphology analysis 
through  digital microscopy, transmission electron microscopy (TEM)  and scanning electron 
microscopy (SEM);  (iii) FTIR spectroscopy;  (iv)  in vitro drug release studies;  and  v)  magnetic 
resonance imaging. To mechanistically elucidate the crosslinking mechanism of lecithin and sodium 
tripolyphosphate with respect to polymethacrylate (Eudragit
®)/chitosan and chitosan, respectively, we 
employed computer-aided modeling of the three-dimensional structure of the active residues of the 
crosslinkers with the respective substrate to predict the possible orientation of residues most likely to 
affect the substrate preference. 
2. Results and Discussion  
2.1. Modeling, Changes in pH and Absorbance of Poly-Lipo Nanoparticles during Fabrication 
Polymeric miscibility was observed between the  methacrylate copolymer and chitosan with no 
visible interactions. Hence, the enhancement of the individual properties of the polymers was 
envisaged to be through blending. Methacrylate copolymer is not as viscous as chitosan due to the fact 
that it has a lower molecular area and topology. Hence, its chemical structure possesses more room for 
incoming entities while chitosan has a larger molecular area with less internal spaces and therefore 
requires less TPP crosslinking compared to the methacrylate copolymer. The similar molecular weight 
units (MW-methacrylate copolymer 968  g/mol and chitosan 972  g/mol) for both polymers were 
energetically minimized qualitatively (as no numerical values of energies were computed  by the 
software) using ACD software in molecular modeling based on three-dimensional (3D) structures of 
the polymeric units but depicted as dot models in Figure 1a–d:  Int. J. Mol. Sci. 2011, 12                       
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Figure 1.  The molecular surface, topology and spaces of the polymers–chitosan and 
methacrylate copolymer for incoming ligands. 
 
A                          B                                   C                        D 
The models obtained were assessed for the maximum unit area occupation  within the given 
(universally equal) rounded squares defined as unit spaces for the static state of the polymeric units as 
follows: (A) chitosan (equimolecular weighted units) at the maximum unit area occupation with the 
highest surface area  in  a  particular 2D dimension;  (B)  methacrylate copolymer (equimolecular 
weighted units) at the maximum unit area occupation with highest surface area in 2D dimension of the 
model; the most area occupancy state; (C) chitosan at the maximum unit area occupation with lowest 
surface area in 2D dimension of the model at static state; the least area occupancy for the rounded 
square sizing unit, (D) methacrylate copolymer (equimolecular weighted units) at the maximum unit 
area occupation with lowest surface area in 2D dimension of the model in static state; the least area 
occupancy state. Thus,  the difference in edges and other 2D matrix areas in the unit space were 
available to the incoming ligands or low molecular weight (LMW) entities. However, in the 3D unit 
space, the difference in area was 0. However, for the longer strands of the polymeric molecule, one 
dimension of the X, Y or Z was comparatively inconsequential or least effective and at a larger scale, 
the structures followed the 2D modeling for available spaces and facility for entry of ligands/LMW 
entities. The 3D illustrations of the  maximum area of occupancy of chitosan and methacrylate 
copolymer as well as the fusion of the two polymers are shown in Figures 2 and 3: 
Figure 2. Space-fill/matrix occupation diagram showing maximum occupancy in unit area 
for (a) chitosan; and (b) methacrylate copolymer. 
(a) 
 
(b) 
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Figure 3.  (a) Space-fill/matrix occupation diagram showing the maximum occupancy   
of methacrylate copolymer and chitosan before blending or fusion in a unit area for   
equal number of molecular weighted polymers (both methacrylate copolymer and   
chitosan-approx mol weight ~12K amu); and (b) fused polymeric matrix containing 
methacrylate copolymer and chitosan. 
(a) 
 
(b) 
 
The nanoparticle synthesis (with incoming entities-lecithin, levodopa and TPP incorporated into the 
polymeric matrix) may follow either of seven patterns depending on the space, sizes of particles being 
formed initially and the presence or absence of turbulence. These patterns are tree branching, nodal 
space fillings, cone array formations, mixed triangular formations, linear patterns, chaotic patterns and 
mixed patterns. Figure 4 shows the octree, 2D and 3D representations of the tree branching pattern. 
The central cross-point (+) in Figure 4a denotes the progenitor point for the nanoparticle synthesis 
start-up which is followed by distribution to available spaces in an evolving 3D patterning-placement 
of emerging nanoparticles. The tree formation is dependent on the space available in the 3D matrix 
area following the branching pattern where the differentiations are outer and inner (back) space bounds 
depending upon the accommodating space for the particles in all directions. 
Figure 4. Tree branching pattern: (a) octree representation; (b) two-dimensional depiction; 
and (c) three-dimensional representation. 
(a) 
 
(b) 
 
(c) 
 
Nodal space filling pattern (Figure 5) was dependent upon the space-fill in nodal points where the 
matrix accommodates the emerging nanoparticles while the node generation was dependent upon the 
changing coordinates of the matrix and their distance parameters (which could accommodate the Int. J. Mol. Sci. 2011, 12                       
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incoming particles). The nanoparticle emergence in this order of patterning is  dependent on the 
available space, size and distribution of the nanoparticles. 
Figure 5. Nodal space fillings: (a) two-dimensional; and (b) three-dimensional representation. 
(a) 
 
(b) 
 
The progenitor area for a cone-array pattern is a circle in the middle as shown in Figure 6. The 
formation of nanoparticles is configured by cone formations where the single lines represent the initial 
alignment  and the merged lines depicting the cone formations onto which nanoparticles align 
simultaneously as they are formed in the medium. The cone-arrays’ distribution within the matrix is 
dictated by the physicochemical properties of the polymeric matrix, the formation of the nanoparticles, 
their optimal formation, grouping and ultimately the thinning density of the emerging nanoparticles 
which may be influenced by synthesis restrictions, raw materials and space limitations. 
Figure 6.  (a) Two-dimensional depiction of cone-array formations; and (b) particle 
development, crowding and thinning of the density (space versus number of particles). 
(a) 
 
(b) 
 
The particle formation in the mixed triangle formation leads toward a triangular shape from the 
progenitor point and the end point tapering in 3D spaces attempting to fill the unit matrix area in all 
plausible directions as shown in Figure 7. The triangles are formed due to the differentiation of the 
nanoparticles and changing shape of the matrix under applied force during experimental conditions 
from nanoparticles which are located along the triangular lines. 
Figure 7. Frontal view of mixed triangle formations of nanoparticles: (a) two-dimensional 
slice representation; and (b) three-dimensional slice representation. 
(a) 
 
(b) 
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Figure 8 represents the linear pattern with progenesis also from the middle with formation of more 
lines of propagation while the nanoparticles are formed on the lines. 
Figure 8. Linear pattern of nanoparticle formation: (a) progenesis and initial propagation; 
(b) more lines of propagation; and (c) two-dimensional model of the matrix containing 
nanoparticles on the lines. 
(a) 
 
(b) 
 
(c) 
 
The chaotic pattern is dependent on the progenesis point and its location in a comparatively   
non-turbulent medium. The formation of nanoparticles may follow any design in the X, Y, Z, top or 
bottom arrangement of the matrix (Figure 9). 
Figure 9. Two-dimensional chaotic pattern of nanoparticle formation. 
       
The mixed pattern in Figure 10 is based on randomization which can occur with a single progenitor 
or multiple progenitors. Multiple progenesis is initiated by the presence of turbulence in the medium. 
Figure 10.  Mixed patterns of nanoparticle formation based on randomizations: (a)  
two-dimensional slice of a single progenitor random patterning; and (b) three-dimensional 
model of single embedded progenitor in a chaotic-random mix state (c) three-dimensional 
model of the multiple progenitors in a chaotic-random mix state based on turbulence in  
the medium. 
(a) 
 
(b) 
 
(c) 
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In summary, it is envisaged that the pattern of  nanoparticle formation that occurred in the 
experimental conditions (agitation) employed in this study is  either mixed triangle formation or   
mixed patterns. 
Lecithin is an anionic phospholipid and surfactant which physically crosslinks the native cationic 
methacrylate copolymer and methacrylate copolymer/chitosan polymeric solutions by electrostatic 
interactions to produce polymer-lipid (poly-lipo) nanoparticles. Studies have confirmed the 
interactions between chitosan and phospholipids (lecithin) [63–68], while the interaction between 
methacrylate copolymer and lecithin was observed in this study. The act of sequestration and 
crosslinking of TPP further binds the components in a nanoparticulate complex. The addition of TPP 
increased the degree of crosslinking which in turn influenced rate of drug release from the poly-lipo 
nanoparticles.  Increase in concentration of polymers and other excipients  increased the pH of the 
nanosuspensions (Table 1). For the polymethacrylate copolymer/chitosan blend, pH increased with the 
addition of each component but the increase was more pronounced when TPP was added. However, 
with methacrylate copolymer alone - B9 and B18, there was no change in pH from the addition of 
levodopa to that of lecithin. 
Table 1. Comparative pH changes during nano-fabrication. 
Formulation 
Code 
Polymer 
Solution 
Addition of 
L-dopa 
Polymer +  
L-Dopa + Lecithin 
Polymer + L-dopa 
+ Lecithin + TPP 
A22  1.17  1.31  1.36  3.15 
B3  1.17  1.34  1.40  1.73 
B6  1.18  1.36  1.41  1.78 
B9  1.13  1.28  1.28  1.68 
B12  1.14  1.19  1.23  1.78 
B13  1.14  1.19  1.23  1.78 
B18  1.13  1.28  1.28  2.37 
B19  1.18  1.36  1.41  2.82 
pH of 0.2N HCL was 1.00. 
White methacrylate copolymer nanoparticles and turbid  methacrylate copolymer/chitosan were 
formed in the presence of lecithin and TPP. On addition of lecithin, a color change (colloidal 
dispersion) was observed indicating the presence of interactions between lecithin (phospholipids) and 
the polymeric solution. The color change could also be due to the formation of capsular wall and 
surfactant activity. Furthermore, the color change may be depicting energy perturbation. The oxygen 
excitation provides the color change–protons are absorbed and the rest of the visible spectrum 
wavelength is reflected back. The addition of TPP to chitosan or methacrylate copolymer/chitosan 
blend gave a creamer color because of the oxygen-related functions (excitable oxygen atoms, 
conjugated oxygen containing groups in higher degree are present in chitosan and TPP). The degree of 
absorbance of visible light increases as lecithin and TPP are added to polymeric solutions (Table 2) 
which is also an indication of color change and subsequent interactions between polymeric solution 
and the ionic agents (lecithin and TPP). However, it is observed that addition of TPP to methacrylate 
copolymer-lecithin blend led to decrease in absorbance. This is due to the fact that chemical 
infrastructure of methacrylate copolymer requires a higher quantity of TPP than utilized to achieve Int. J. Mol. Sci. 2011, 12                       
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sufficient particulate complexation. An increase in TPP generates drier, free flowing particles. This is 
attributed to increased quantity of TPP causing less room in the particles matrices for solvent and 
water molecules. From the modeling, the morphology of the nanoparticles formed is suggested to be 
nanocapsules, loosely filled hollow capsules or solid spherical particles. 
Table 2. Changes in absorbances during nano-fabrication. 
Polymer Composition  Polymer Solution  Addition of Lecithin  Addition of TPP 
EE100  0.0135  0.5681  0.4876 
Chitosan  0.1382  3.3501  3.5597 
EE100 + Chitosan  0.0589  2.7885  3.1930 
EE100-methacrylate copolymer. 
2.2. Size and Surface Charge Analyses of Poly-Lipo Nanoparticles 
The average particle sizes of the nanoparticles after the addition of lecithin ranged from 152 nm  
for methacrylate copolymer only to 321  nm for methacrylate copolymer/chitosan blend while the   
zeta potential ranged from 15.8 to 43.3 mV. As the quantity of chitosan increased, the particle size 
increased. Furthermore, since the degree of crosslinking was increased by the addition of TPP, the 
particle size increased to average particle size of 424 nm. The polydispersity index ranged from 0.19 to 
0.61. Formulation of poly-lipo nanoparticles as nanosuspension may require increased quantity of TPP 
to ensure free flowing nanoparticles. When administered as nanosuspension, it is envisaged that, based 
on the mucoadhesive property of chitosan, the nanoparticles will adhere to the mucosal wall of the 
duodenum while levodopa is being released into the systemic circulation. Hence, the focus may be on 
obtaining free flowing particles to ensure effective packaging rather than obtaining a particle size 
below 100 nm.  
2.3. Fourier Transform Infra-Red (FTIR) Spectroscopy of the Poly-Lipo Nanoparticles 
The spectra as shown in Figure 11 exhibited the chemical structural transitions that had occurred 
during nanofabrication by multi-crosslinking. In comparison with the spectra of the native polymers, 
the spectra of the nanoparticles showed absence of some peaks found in the native polymers such as at 
frequencies of 2769.74 cm
−1 and 1268.73 cm
−1 for methacrylate copolymer; 3357.51 cm
−1, 1590.66 cm
−1 
and 1024.66  cm
−1  for chitosan with emergence of new peaks after crosslinking at 1605  cm
−1  
which was found in methacrylate copolymer nanoparticles as well  as the blend (methacrylate 
copolymer/chitosan); 1519  cm
−1  in methacrylate copolymer which slightly shifted in the blend to 
1518.75–1522.24 cm
−1 (envisaged to be determined by the degree of crosslinking in each nanoparticles 
formulation). Also, the peaks in the native polymers, which may be considered to still exist, shifted.  
For example: the peak at 2949.11 cm
−1 in methacrylate copolymer shifted to 2923.91 cm
−1; 1722.39 
cm
−1 shifted to 1724.86 cm
−1 and 891.80 cm
−1 in chitosan shifted to 889.79 cm
−1. The distinct aldehyde 
functional group (C=O) found in methacrylate copolymer at 1722.46 cm
−1 and in lecithin at 1722.16 
cm
−1 was found in the nanoparticles at 1727.97 cm
−1 (Figure 11a and b). The disappearance of peaks 
and emergence of new peaks is attributed to the interactions between the ionic agents leading to 
polymer-lipid-salt particulate complex. The differences between spectra of methacrylate copolymer Int. J. Mol. Sci. 2011, 12                       
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nanoparticles and methacrylate copolymer/chitosan nanoparticles as shown in Figure 11c are found at 
the O-C bands (1056.09 cm
−1 and 1013.64 cm
−1) and at 824.73 cm
−1 of methacrylate copolymer while 
the other peaks which are similar in both did not absorb at exactly the same place. Some peaks have a 
difference in absorbance frequencies of 1, 2 or 3 cm
−1. No additional difference was found when 
benserazide was incorporated (Figure 11d) which may be an indication that the drugs–levodopa and 
benserazide did not interact with other components or due to the small quantity of benserazide and its 
similarity in structure to levodopa; there was no observed distinct peak for it (benserazide).  
Figure 11.  FTIR spectra of: (a) the various components employed for fabrication of 
nanoparticles as well as the fabricated levodopa-loaded nanoparticles; (b) levodopa-loaded 
nanoparticles; (c) methacrylate copolymer nanoparticles and methacrylate copolymer/chitosan 
nanoparticles; and (d) levodopa- and levodopa/benserazide-loaded nanoparticles. 
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2.4. Surface Morphology of the Poly-Lipo Nanoparticles 
Spherically structured nanoparticles were observed as viewed under the digital microscope before 
lyophilization. Figure 12 shows digital images of methacrylate copolymer/chitosan crosslinked with 
lecithin only and multi-crosslinked methacrylate copolymer nanoparticles. The smaller sizes of 
methacrylate copolymer nanoparticles as compared to the polymeric blend with chitosan were further 
confirmed by the digital images. 
 
Figure 12.  Digital images of: (a)  methacrylate copolymer/chitosan crosslinked with 
lecithin alone; and (b) mulit-crosslinked  methacrylate copolymer  nanoparticles 
(magnification ×32). 
(a) 
 
(b) 
 
TEM confirmed the capsular wall of the levodopa-loaded nanoparticles (Figure 13) while SEM 
displayed the hollow spherical nanocapsules (Figure 14). 
Figure 13. Transmission electrom microscopic images of levodopa-loaded polymethacrylate 
copolymer/chitosan poly-lipo nanoparticles: (a) magnification ×20000; and (b) 
magnification ×8000. 
(a) 
 
(b) 
 
a)  b) 
a) Int. J. Mol. Sci. 2011, 12                       
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Figure 14. Scanning electron microscopic images of levodopa-loaded polymethacrylate 
copolymer/chitosan poly-lipo nanoparticles: (a) magnification ×5000; and (b) 
magnification ×5500. 
(a) 
 
(b) 
 
2.5. Drug Loading Efficiency of Poly-Lipo Nanoparticles 
The drug loading efficiency was found to be 93%. The poly-lipo nanoparticles had a high drug 
entrapment efficiency of 85% and though the fabrication was stepwise there was no washing, 
centrifuging or decanting. It is envisaged that drug incorporation into the nanoparticles is a 
combination of encapsulation and surface adsorption. 
2.6. Direct Compression of Poly-Lipo Nanoparticles into Tablet Matrices 
All formulations of L-dopa-loaded nanoparticles were directly compressible. Direct compression is 
indeed a pharmaceutical technique employed for moisture-sensitive drugs such as L-dopa. Moisture, 
being one of the major causes of instability of drugs, is not utilized in direct compression, unlike wet 
granulation. The compressibility of the nanoparticles demonstrated the inherent compaction of the 
polymers which was not eliminated by the process of fabrication of the nanoparticles. 
2.7. In vitro Drug Release Studies 
By the 5th hour, nanosuspensions had released more than 60% of L-dopa while all except B12 and 
B6 released more than 50% within two hours (Figure 15). Hence Levodopa-loaded nanosuspension 
can be employed for rapid relief of parkinsonian symptoms. The nanoparticles are anticipated to 
adhere to the mucosal walls by electrostatic interactions thereby improving the bioavailability of   
L-dopa. L-dopa release from nanosuspension into the two buffers utilized (pH 1.5 and 4.5) did not 
differ significantly as shown in Figures 15a and 15b. By the 24th hour, 86–94% of L-dopa was 
released. However, the release profiles in buffers differed upon incorporating the nanoparticles into an 
interpolymeric blend (Figures 16a,b)  which may be  due to the pH responsive nature of the 
interpolymeric blend. As pH increased, the rate of release of L-dopa decreased. Furthermore, the 
fractional drug released by 24th hour from the interpolymeric blend was less when compared to Int. J. Mol. Sci. 2011, 12                       
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nanosuspension due to increased barrier and subsequent diffusion distance. While 78% drug release 
was the highest released in buffer pH 1.5 by one of the nanoparticulate compositions, 46% was the 
lowest released in buffer pH 4.5 by the 24th hour. 
Figure 15. (a) Drug release profiles of L-dopa-loaded nanoparticles employing dialysis 
technique in pH 1.5 buffer; and (b) drug release profiles of L-dopa-loaded nanoparticles 
employing dialysis technique in pH 4.5 buffer. 
(a) 
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Figure 16. (a) Drug release profiles of L-dopa-loaded nanoparticles incorporated into an 
interpolymeric blend in pH 1.5 buffer; and (b) drug release profiles of L-dopa-loaded 
nanoparticles incorporated into an interpolymeric blend in pH 4.5 buffer. 
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Comparing drug release profiles from the three formulations–nanosuspension, compressed 
nanoparticles and nanoparticles compressed within an  interpolymeric blend, it was observed that 
incorporating methacrylate copolymer nanoparticles into an interpolymeric blend produced a sustained 
release of L-dopa as compared to direct compression of the nanoparticles alone (Figure 17a). Since 
buffer pH 1.5 percolates the compressed methacrylate copolymer nanoparticles, the particles are 
dispersed in the buffer such that 75% of levodopa is released into the medium at the 1st hour. On the 
other hand, directly compressed L-dopa-loaded methacrylate copolymer/chitosan nanoparticles remained 
basically intact with swelling and slight erosion over 24 h with release of L-dopa almost comparable to 
the release profile of the nanoparticles incorporated into an interpolymeric blend (Figure 17b). Int. J. Mol. Sci. 2011, 12                       
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Figure 17.  (a) Comparative drug release profiles of the different formulations of   
levodopa-loaded methacrylate copolymer nanoparticles (B18) in pH 1.5; and   
(b) comparative drug release profiles of the different formulations of levodopa-loaded 
methacrylate copolymer/chitosan nanoparticles (B19) in pH 1.5. 
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2.8. Polymeric Nanoparticles Improve Mechanical Strength 
The interpolymeric blend being pH responsive maintained its three-dimensional network in pH 1.5 
but underwent surface erosion in higher pH such as 4.5. However, in the presence of incorporated 
nanoparticles, the three-dimensional network was maintained in both buffer types over the 24 h drug 
release studies. The mechanical strength of the interpolymeric blend was improved in pH 4.5 by the 
electrostatic interactions between the nanoparticles and the interpolymeric blend. Studies have shown Int. J. Mol. Sci. 2011, 12                       
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that nanoparticles can be employed to improve the mechanical strength of matrices [69–75]. These 
studies utilized inorganic nanoparticles to improve mechanical properties. However, in this study 
polymeric nanoparticles improved the mechanical strength of a polymeric matrix preventing the 
polymeric matrix’s erosional response at a higher pH. The pictorial diagram of the impact of nanoparticles 
on the mechanical strength of the interpolymeric blend matrix is shown in Figures 18 and 19. 
Figure 18. (a) Interpolymeric tablet matrix loses; and (b) its three-dimensional shape as 
the pH increases to 4.5 after dissolution studies. 
                   
Figure 19. (a) interpolymeric tablet matrix shape retained; and (b) its three-dimensional 
shape in pH 4.5 when polymeric nanoparticles are incorporated into it. 
                     
2.9. Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) was also employed to observe and confirm the mechanical 
behaviors that occurred during dissolution studies. Figure 20A displays the images obtained at pH 1.5 
upon incorporating the nanoparticles into the interpolymeric blend. Figure 20B shows interpolymeric 
blend without nanoparticles at pH 4.5 while Figure 20C shows the mechanical behavior of the matrix 
upon incorporating the nanoparticles into the interpolymeric blend at pH 4.5. The images shown were 
obtained at zero, 3, 6, 9 and 12 h. The grey part surrounding the matrix is the dissolution medium 
(buffer). The black part within the matrix is the non-hydrated and non-gelled part of the tablet. As the 
matrix hydrated, it swelled and gelled, which is shown by the white part, and its thickness increased 
over time until the matrix was fully hydrated and gelled. As shown, the matrix is a hydrogel which 
retains its three-dimensional network (shape) at pH 1.5. Figure 20B confirmed the gradual surface 
a) 
a)    b) 
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erosion that occurs at pH 4.5 without the nanoparticles. The matrix loses its shape at pH 4.5 as it 
hydrates, erodes and gels. Rapid erosion was not observed because three polymers were employed to 
prepare the interpolymeric blend with two of them forming interpolyelectrolyte complex. It is typical 
for hydrogel matrices produced with high-molecular weight polymers not to exhibit rapid erosion as 
their helical chains form rigid interactions within the polymer molecules [76]. Usually it requires more 
than 24 h for the interpolymeric blend to erode completely. However, when nanoparticles were added, 
at pH 4.5 the matrix retained its shape with less penetration of solvent into the matrix as the thickness 
of the white part was less when compared to images in Figure 20A and consequently less swelling. 
Hence, magnetic resonance imaging confirmed the mechanical influence of nanoparticles on polymeric 
matrices. 
Figure 20. Magnetic resonance images of the mechanical behavioral changes of matrices 
in different pHs: (A) nanoparticles incorporated into interpolymeric blend at pH 1.5;   
(B) interpolymeric blend matrix without nanoparticles at pH 4.5 (C) nanoparticles 
incorporated into interpolymeric blend at pH 4.5 at 0, 3, 6, 9 and 12 h. 
         
 
         
 
         
 
2.10. Molecular Mechanics Assisted Model Building and Energy Refinements 
A molecular mechanics conformational searching procedure was employed to acquire the data 
employed in the statistical mechanics analysis, and to obtain differential binding energies of a   
Polak–Ribiere algorithm and to potentially permit application to PR and TPP-mediated crosslinking of 
9 h 
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E100/CHT polymer composite assemblies.  MM+ is a HyperChem modification and extension of 
Norman Allinger’s Molecular Mechanics program MM2 [77],  whereas AMBER, is a package of 
computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and 
free energy calculations to simulate the structural and energetic properties of molecules [78]. 
2.10.1. Molecular Mechanics Energy Relationship (MMER) Analysis 
Molecular mechanics energy relationship (MMER), a method for analytico-methematical 
representation of potential energy surfaces, was used to provide information about the contributions of 
valence terms, noncovalent Coulombic terms, and noncovalent van der Waals interactions for the 
crosslinked-polymer morphologies. The MMER model for the potential/steric energy factors in various 
molecular complexes can be written as: 
Emolecule/complex = V∑ = Vb + Vθ + Vφ + Vij + Vhb + Vel  (1)  
ECHT =35.555V∑ = 3.120Vb + 18.035Vθ + 25.774Vφ + 13.323Vij − 24.697Vel  (2)  
EPR = 6.717V∑ = 0.145Vb + 2.477Vθ + 4.743Vφ − 0.484Vij − 0.163Vhb  (3)  
ECHT-PR = 22.230V∑ = 12.683Vb + 1.875Vθ + 27.680Vφ + 7.176Vij − 0.596Vhb − 26.757Vel  (4)  
[ΔEBINDING = −33.476 kcal/mol] 
EE100 =100.577V∑ = 10.018Vb + 45.058Vθ + 13.454Vφ + 32.052Vij − 0.0068Vhb  (5)  
EE100-PR = 89.724V∑ = 10.579Vb + 57.476Vθ + 39.343Vφ − 16.028Vij − 1.647Vhb  (6)  
[ΔEBINDING = −24.287 kcal/mol] 
EE100-PR-CHT = 39.230V∑ = 13.645Vb + 89.514Vθ + 91.042Vφ − 122.797Vij − 2.847Vhb 
 − 29.327Vel 
(7)  
[ΔEBINDING = −150.638 kcal/mol] 
ETPP = 199.744V∑ = 1.927Vb + 93.088Vθ + 1.599Vφ + 0.046Vij + 103.082Vel  (8)  
ECHT-TPP = 901.408V∑ = 18.542Vb + 514.621Vθ + 54.501Vφ + 28.920Vij − 1.065Vhb + 285.889Vel  (9)  
[ΔEBINDING = −132.867 kcal/mol] 
where,  V∑  is related to total steric energy for an optimized structure, Vb  corresponds to bond 
stretching contributions (reference values were assigned to all of a structure’s bond lengths), Vθ denotes 
bond angle contributions (reference values were assigned to all of a structure’s bond angles), Vφ 
represents torsional contribution arising from deviations from optimum dihedral angles, Vij 
incorporates
  van der Waals interactions due to non-bonded interatomic distances, Vhb  symbolizes 
hydrogen-bond energy function and Vel stands for electrostatic energy. Int. J. Mol. Sci. 2011, 12                       
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2.10.2. Energy-Minimizations Involving Crosslinked-Polymer Morphologies 
The energy changes brought about by crosslinking of E100 and Chitosan with PR are given in 
equations 2 to 6 and the resulting geometrical minimizations are depicted in Figure 21. The total 
change in energy is calculated as the sum of an internal energy component, calculated from bond 
stretching, angle bending, and torsional rotation, and a non-bonded component calculated from 
coulombic and van der Waals interactions. It is evident from Figure 21a that PR may crosslink CHT by 
forming hydrogen bonds between their functional groups such as PO4
−… NH, NH… OH
− and NH… 
NH crosslinking. The ΔEBINDING = -33.476 kcal/mol proved that CHT-PR forms a stable structure 
stabilized by all the three non-bondng interactions viz., van der Waals forces, hydrogen bonding and 
electrostatic interactions with London dispersion forces playing the major part (Equations 4–6). These 
interactions confirmed the previously reported interactions between chitosan and phospholipids 
(lecithin) as discussed earlier [63–68]. 
Figure 21.  Visualization of geometrical preference of Phospholipid residues in 
complexation with: (a) Chitosan; and (b) Eudragit E100 after molecular mechanics 
simulations. The atoms forming the hydrogen bonds are emphasized by dotted lines after 
recomputing the H bonds after energy minimizations. Color codes: C (cyan), O (red),   
N (blue), P (yellow) and H (white). 
(a) 
 
(b) 
 
It is apparent form Figure 21b that E100 can also be crosslinked by PR, as postulated earlier in the 
paper, forming both intra- and inter-molecular bonding. Figure 21b depicts that the complexing of Int. J. Mol. Sci. 2011, 12                       
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phosphate with amine group proceeds via formation of both the hydrogen bond NH... O=P and CO… 
O=P and also the N
δ−...p
δ+  bond  [79]. The formation of stabilized structure of E100-PR with   
ΔEBINDING  =  -24.287  kcal/mol also confirms the crosslinking action of TPP. The main difference 
between CHT-PR and E100-PR crosslinking is that there is no electrostatic interaction involved 
between E100 and PR. E100-PR is thus stabilized mainly by van der Waals hydrophobic interaction 
and negligibly by H-bonding (Equations 5 and 6). The above crosslinking reactions are formed the 
basis of our postulation,  which states that the incorporation of lecithin might act as a bridge for 
interpolymeric crosslinking. To elucidate this concept, we modeled E100 and CHT together with PR 
(E100-PR-CHT), molecularly dispersed within the polymeric matrix (Figure 22). After global energy 
and geometry minimization, we observed that it is possible for PR to form an interpolymeric bridge 
between E100 and CHT as depicted in Figure 23c. Surprisingly, the ΔEBINDING for the trimolecular 
complex was -150.638 kcal/mol, which was ~5 times more stabilized than the individual polymer 
complex of  E100-PR or CHT-PR (Equation 7). 
Figure 22.  Visualization of geometrical preference of Chitosan and Eudragit in 
complexation with Phospholipid residues (PR) after molecular mechanics simulations:   
(a) E100-PR-CHT molecular complex in full geometry; (b) Connolly molecular 
electrostatic potential surfaces in transparebt display mode showcasing the nanoparticlulate 
system; and (c) A typical conformation showcasing the bridging of E100 and CHT by 
phospholipid residue. Color codes: C (cyan), O (red), N (blue), P (yellow) and H (white). 
 
 
a
 
b Int. J. Mol. Sci. 2011, 12                       
 
 
6214 
Figure 22. Cont. 
 
Figure 23.  Visualization of geometrical preferences of TPP (stick rendering) in 
complexation with CHT (tube rendering) after molecular mechanics simulations. Color 
codes: C (cyan), O (red), N (blue), P (yellow) and H (white). 
 
The final conformation model of E100-PR-CHT molecular network was generated for formable 
complex structures in relation to the cooperative ion-pair binding of the carbonyl (−CO), hydroxyl 
(−OH
−), protonated amine (−NH3
+) groups of the polymers with the quaternary phosphonium ion   
(PO4
−) and protonated amine (−NH3
+) groups of the crosslinker (Figure 21a). The strong binding 
affinity in E100-PR-CHT was due to the hydrophobic interactions and charge distribution caused by 
the interacting moieties which act in co-operation with the short range van der Waal attractions and 
secondary interactions such as hydrogen bonding (Equation 7). Interestingly, the stabilized van der 
Waals energy demonstrated the importance of a structural backbone fit between the host and guest 
molecule. Figure 21b depicts the energy-minimized van der Waal radii structure of E100-PR-CHT 
where, due to the flexibility of the polymer chains, the relevant segments of polymers arrange their 
configuration to form a remarkable structure fit between the various functional groups, the 
electrostatic, van der Waals and H-bond interactions being almost optimized. 
Apart from these, the chitosan polymeric matrix in particular was further stabilized and crosslinked 
due to the addition of sodium tripolyphosphate (TPP) as shown in Figure 23 and Equations 8 and 9. 
The CHT-TPP molecular complex demonstrated a ΔEBINDING of -132.867 kcal/mol. The complex is 
c Int. J. Mol. Sci. 2011, 12                       
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mainly stabilized by nonbonding interactions in terms of London dispersion forces, H-H bonding and 
ion pair-ion pair electrostatic interactions (Equations 8 and 9). However, it is apparent in Figure 23 that 
direct linking of adjacent glucosamine units may have brought about the largest change in energy 
relative to uncrosslinked states. The following possible crosslinks were formed: PO4
−-OH crosslinking, 
PO4
−-NH crosslinking, OH-PO4
−-OH crosslinking, NH-PO4
−-NH  crosslinking and   
OH-PO4
−-NH crosslinking. 
Although the complex morphologies were finally stabilized by dominating non-bonding 
interactions, the chain interactions culminating from the crosslinking agents such as Lecithin (a 
phospholipid) and sodium tripolyphosphate (conjugate base of triphosphoric acid) may cause 
disturbance at high crosslink densities resulting in distortion of bond lengths, angles, and torsions from 
their equilibrium values eventually causing strained-unstable-rigid-framework (Figure 22b). 
Additionally, the intermolecular crosslinking may initiate a significant axial stress due to buildup of 
the adjacent crosslinks. This provides a reasonable explanation for the experimentally observed 
controlled release behavior of the nanoparticle formulations due to formation of a dense polymeric 
matrix owing to this very crosslinking mechanism of PR and TPP. 
These modeling results are in corroboration with the observed experimental results where it was 
postulated that the color change after the addition of crosslinking agent may be due to energy 
perturbation. Additionally, free flowing particles generated after the inclusion of TPP may be further 
attributed to less space in the particles’ matrices for solvent and water molecules due to the matrix 
stability and robustness displayed in energy minimized geometrical configurations. Furthermore, this 
matrix stability and robustness may induce a low degree of matrix loss, minimal swelling and limited 
distension resulting in a sustained and prolonged release of levodopa from the nanoparticle 
formulations. The spectral analysis also corroborated with the mechanistic simulation in terms of 
disappearance of peaks and emergence of new peaks along with band shifting and broadening involved 
in coupling and complexation (FTIR structural variation analysis) which strengthens the experimental 
and computational correlation. 
3. Experimental Section 
3.1. Materials 
Methacrylate copolymer (Eudragit E100) was purchased from Evonik Röhm GmbH & Co. KG 
(Evonik Röhm GmbH and Co. KG, Darmstadt, Germany), chitosan (food grade), (Wellable group, 
Fujian, China), sodium tripolyphosphate (TPP) (Sigma-Aldrich, Steinheim, Germany), lecithin from 
egg yolk (Lipoid E PC S, a gift from Lipoid AG, Ludwigshafen, Germany), 3-(3,4-Dihydroxyphenyl)-
L-alanine (levodopa), potassium phosphate monobasic (KH2PO4) (Sigma-Aldrich Inc., Steinheim, 
Germany), acetic acid glacial, hydrochloric acid (HCl) (Rochelle Chemicals, Gauteng, South Africa), 
potassium chloride  (KCl) (Saarchem, Krugersdorp, South Africa), ortho-phosphoric acid (BDH 
Chemicals, Poole, England) and chloroform (Rochelle Chemicals, Gauteng, South Africa). All other 
reagents used were of analytical grade and were employed as purchased. 
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3.2. Nanofabrication of Polymer-Lipid Nanoparticles 
Weighed quantities of methacrylate copolymer and varying quantities of methacrylate copolymer 
with chitosan were dissolved in 10 mL 0.2N HCl and 100 mg of L-dopa was added into the polymeric 
solution. Lipoid E PC S (100 mg) was dissolved in 1mL of chloroform and added to levodopa-loaded 
polymeric solution under mechanical agitation for 10 min. Varying concentrations of TPP dissolved in 
0.2 N acetic acid were added under agitation for another 10 min, pre-freezed at - 70 °C for 24 h and 
thereafter lyophilized for 48 h. The different formulations of nanoparticles are shown in Table 3. 
Table 3. Components and the respective quantities employed for nanoparticles formation. 
S/N  Formulation 
Code 
Eudragit 
(mg) 
Chitosan 
(mg) 
L-dopa 
(mg) 
Lecithin 
(mL) 
TPP  
(mg) 
1  A22  150  150  100  1.00  250 
2  B3  150  50  100  1.00  50 
3  B6  100  100  100  1.00  50 
4  B9  200  –  100  1.00  50 
5  B12  50  50  100  1.00  100 
6  B18  200  –  100  1.00  150 
7  B19  100  100  100  1.00  150 
8  C0  –  200  100  1.00  150 
9  C1  –  200  100  1.00  – 
10  B180  200  –  100  1.00  – 
11  B190  100  100  100  1.00  – 
3.3. Determination of pH and Absorbance Changes During Fabrication 
Initial pH values for the polymer solutions were obtained followed by changes in pH during the 
addition of the polymer solutions (in a stepwise manner) to the acidic media. Hence, four pH values 
were obtained at the end of fabrication. The changes in absorbance from the polymer solution, on 
addition of lecithin and TPP afterwards were obtained. The absorbance changes were obtained in the 
absence of Levodopa (L-dopa) 
3.4. Computational Modeling of the Fabrication of Multi-Crosslinked Nanoparticles 
Computational modeling was performed to expound the interactions between the polymers and the 
crosslinking agents as well as the mechanism of the formation of nanoparticles. Models and graphics 
depicting the mechanisms of interactions were generated on ACD/l-Lab, V5.11 (Add-on) software 
(Advanced Chemistry Development Inc., Toronto, Canada, 2000). Interactions were interpreted by 
employing some general chemistry concepts and chemometric modeling concepts. 
3.5. Size and Surface Charge Analyses of the Poly-Lipo Nanoparticles 
Nanoparticle size, size distribution as well as zeta potential analyses  were  carried out  using 
ZetaSizer NanoZS (Malvern Instruments, Malvern, UK) instrument equipped with non-invasive Int. J. Mol. Sci. 2011, 12                       
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backscatter technology set at an angle of 173°. The nanoparticles sizes and zeta potentials were 
profiled following the addition of lecithin, then after addition of TPP and finally after lyophilization. 
3.6. Fourier Transform Infra-Red (FTIR) Spectroscopy of the Poly-Lipo Nanoparticles 
FTIR spectra over the range of 4000–650 cm
−1 were obtained for the native polymers employed  
and the poly-lipo nanoparticles using a PerkinElmer spectrometer (PerkinElmer Spectrum 100, 
Beaconsfield, United Kingdom) to elucidate the chemical structural transitions that occurred   
during nanofabrication. 
3.7. Microscopical Analysis of the Levodopa-Loaded Poly-Lipo Nanoparticles 
The surface morphology analyses of the poly-lipo nanoparticles were undertaken by performing 
digital microscopy, transmission electron microscopy (TEM) and scanning electron microscopy 
(SEM). The digital microscopical images of the poly-lipo nanoparticles after synthesis were obtained 
using Olympus digital microscope; Olympus SZX-ILLD2-200 (Olympus Corporation, Tokyo, Japan). 
The nanosuspension was diluted tenfold with deionized water and drops were deposited on formvar 
coated nickel grids. They were allowed to dry in sealed petri dish and later viewed under TEM   
(JEOL-JEM 100S transmission electron microscope, Tokyo, Japan). Furthermore, lyophilized 
nanoparticles were thinly spread on a carbon tape, coated with gold-palladium and viewed under SEM 
(JEOL-JEM 840 scanning electron microsope, Tokyo, Japan) at a voltage of 15 keV and current   
6 × 10
−10 Amp. 
3.8. Determination of Drug Loading and Drug Entrapment Efficiency of the Poly-Lipo Nanoparticles 
Percentage drug loading efficiency was determined gravimetrically to assess the capacity of the 
nanoparticles with regards to the amount of the loaded drug in the nanoparticles. The percentage drug 
loading was calculated based on the weights of the incorporated drug and the nanoparticles employing 
Equation 10: 
 
(10)  
The drug entrapment efficiency was determined by dispersing the poly-lipo nanoparticles in 0.1N 
HCl and the amount of the drug in the medium was assessed spectrophotometrically to obtain the 
amount of drug in the poly-lipo nanoparticles with respect to the amount of drug used in the 
fabrication, employing Equation 11: 
 
(11)  
 
Amount of nanoparticles 
Amount of drug in nanoparticles 
Drug Loading (%) =    × 100 
Theoretical amount of drug 
Actual Amount of drug  
Drug entrapment efficiency (%) =    × 100 Int. J. Mol. Sci. 2011, 12                       
 
 
6218 
3.9. Direct Compression of the Poly-Lipo Nanoparticles 
3.9.1. Exclusive Direct Compression of the Poly-Lipo Nanoparticles 
The lyophilized poly-lipo nanoparticles were directly compressed without additives or excipients in 
order to elucidate their drug release profiles unaided. The compression was undertaken employing a 
Carver hydraulic press (Carver Industries Inc., Wabash, IN, USA) at 3 tons. 
3.9.2. Incorporation of Poly-Lipo Nanoparticles into an Interpolymeric Blend 
The incorporation of poly-lipo nanoparticles into the interpolymeric blend was undertaken by 
employing an interpolymeric blend (IPB) comprised of methacrylate copolymer, carboxymethyl 
cellulose and locust bean. The L-dopa loaded poly-lipo nanoparticles were blended with the 
interpolymeric blend without adding any other excipients or additives. The nanoparticles-loaded 
interpolymeric blend was directly compressed employing Carver hydraulic press (Carver Industries 
Inc., Wabash, IN, USA) at 3 tons. The composition of the nanoparticles utilized for incorporation into 
the interpolymeric blend is shown under Section 3.2, Table 3 (S/N 1-7). 
3.10. In vitro Drug Release Studies 
Drug release was assessed using USP apparatus II dissolution system (Erweka DT 700, Erweka 
GmbH, Heusenstamm, Germany). Temperature and stirring rate were 37  ±  0.5  °C and 50  rpm 
respectively while the dissolution media were 900 mL buffer pH 1.5 (standard buffer KCl/HCl) and 
pH 4.5 (0.025 M KH2PO4/H2PO4). Samples were withdrawn at intervals and replaced with the same 
volume of fresh medium to maintain sink conditions. The amount of L-dopa released was quantified 
using UV spectrophotometer (LAMBDA 25 UV/Vis spectrophotometer, PerkinElmer, MA, USA). The 
drug release profiles were obtained from three formulations of L-dopa-loaded nanoparticles. 
3.10.1. Drug Release Studies of Nanosuspension Employing Dialysis Technique 
Various quantities (depending on the varying composition) of L-dopa-loaded nanoparticles 
dispersed in 10mL of dissolution media; buffer pH 1.5 (standard buffer KCl/HCl) and pH 4.5 (0.025 M 
KH2PO4/H2PO4) at separate periods were introduced into dialysis tubing (Dialysis tubing cellulose 
membrane, Ave flat width–33  mm, diameter–21  mm when full, M.W. 12,400, Sigma Aldrich, 
Steinheim, Germany). Both ends of the tubing were tightly sealed and placed in a dissolution vessel 
with 900 mL of buffer and stainless ring-mesh assemblies were employed to keep the tubings in place 
to prevent erratic floatation due to unstable hydrodynamics above the paddle. Before incorporation of 
nanoparticles into the tubing, the dialysis tubing was immersed in deionized water for 3 h to remove 
glycerol and sulfide from the tubing. The drug release studies were conducted over 24 h. 
3.10.2. Drug Release Studies of the Compressed Matrices 
The second and third drug release studies involved the matrices of the L-dopa-loaded nanoparticles 
alone and the L-dopa-loaded nanoparticles incorporated into an interpolymeric blend in pH 1.5 buffer Int. J. Mol. Sci. 2011, 12                       
 
 
6219 
(standard buffer KCl/HCl) and pH 4.5 (0.025  M KH2PO4/H2PO4) over 24 h. The apparatus and 
parameters employed for dissolution are as stated above. 
3.11. Magnetic Resonance Imaging of Mechanical Behavior 
A magnetic resonance system with digital MARAN-i System configured with a DRX2 HF 
Spectrometer console (Oxford Instruments Magnetic Resonance, Oxon, UK) equipped with a compact 
0.5 Tesla permanent magnet stabilized at 37 °C and a dissolution flow through cell was employed for 
the viewing of the mechanical behaviors of the matrices. After duly configuring, optimizing the shims 
and probe tuning, the cone-like lower part of the cell was filled with glass beads to provide laminar 
flow at 16 mL/min of the solvents employed. The matrices were placed in position each time within 
the cell which in turn was positioned in a magnetic bore of the system and magnetic resonance images 
were acquired hourly over 12 h with MARAN-i version 1.0 software. The image was acquired after 
setting the frequency offset and testing gain employing RINMR version 5.7 under continuous solvent 
flow conditions. MARAN-i software comprises image acquisition software and image analysis 
software. The image acquisition parameters are depicted in Table 4. 
Table 4. Image acquisition parameters applied during magnetic resonance imaging using 
MARAN-i. 
S. No.  Parameter  Value 
1.  Imaging protocol  FSHEF 
2.  Requested gain (%)  1.90 
3.  Signal strength  71.62 
4.  Average  2 
5.  Matrix size  128 
6.  Repetition time (ms)  1000.00 
7.  Spin Echo Tau (ms)  6.00 
8.  Image acquired after  60 min 
9.  Total scans  64 
3.12. Static Lattice Atomistic Simulations 
Molecular Mechanics Computations in vacuum, which included the model building of the   
energy-minimized  structures of multi-polymer-crosslinker complexes,  were performed using the 
HyperChem
TM  8.0.8 Molecular Modeling System (Hypercube Inc., Gainesville, FL, USA) and 
ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, Cambridge, UK) [80]. The structures of Eudragit 
(E100-four monomer units), Phospholipid residues (PR) and TPP were generated as a 3D model from 
standard bond lengths and angles employing ChemBio3D Ultra whereas the structure of chitosan 
(CHT-ten glucosamine oligosaccharide units) was generated using  sugar builder module on 
HyperChem 8.0.8. The generation of the overall steric energy associated with the energy-minimized 
structures was initially executed via energy-minimization using MM+ force field and the resulting 
structures were again energy-minimized using the Amber 3 (Assisted Model Building and Energy 
Refinements) force field. The conformer having the lowest energy was used to create the   
polymer-crosslinker complexes. A complex of one molecule with another was assembled by disposing Int. J. Mol. Sci. 2011, 12                       
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them in a parallel way, and the same procedure of energy-minimization was repeated to generate the 
final models: CHT-TPP, CHT-PR, E100-PR and E100-PR-CHT. Full geometry optimizations were 
carried out in vacuum employing the Polak–Ribiere conjugate gradient method until an RMS gradient 
of 0.001 kcal/mol was reached. Force field options in the AMBER (with all hydrogen atoms explicitly 
included) and MM+ (extended to incorporate non-bonded cut-offs and restraints) methods were the 
HyperChem 8.0.8 defaults. For calculations of energy attributes, the force fields were utilized with a 
distance-dependent dielectric constant scaled by a factor of 1. The 1–4 scale factors are following: 
electrostatic 0.5 and van der Waals 0.5 [80].  
4. Conclusions 
This study demonstrates the feasibility of fabricating of L-dopa-loaded nanoparticles. The obtained 
nanoparticles were hollow, capsular, nanoparticulate complex with 93% drug loading efficiency. The 
desired rate of drug release from methacrylate copolymer can be modulated by formulating levodopa-
loaded nanoparticles as a suspension, then directly compressing the nanoparticles into a tablet matrix 
or by loading the nanoparticles into a polymeric blended tablet matrix. Twenty-four hour sustained 
release of levodopa from methacrylate copolymer nanoparticles was achieved by embedding the 
nanoparticles within an interpolymeric blended tablet matrix while sustained drug release from 
methacrylate copolymer/chitosan nanoparticles can be achieved by directly compressing the 
nanoparticles into a tablet matrix. This study also elucidates the potentials of polymeric nanoparticles 
to enhance the mechanical strength of polymeric matrices. Furthermore, experimental and theoretical 
investigations on the effect of crosslinking on the release of L-dopa  from  the nanoparticles 
formulations were in excellent agreement. The experimentally observable drug release could be 
predicted by the computational method and the energy calculations allowed for a prediction of the 
interaction mechanisms. The developed delivery system may find applications in oral, sustained and 
localized drug delivery. 
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